An anticancer compound is disclosed which is represented by the formula ##STR1## wherein one of R.sup.1 and R.sup.2 is a phenyl-lower alkyl optionally having a substituent, phenyl-lower alkenyl or naphthyl-lower alkyl, the other of R.sup.1 and R.sup.2 is hydrogen or acyl, and R.sup.3 is hydrogen, acyl or tetrahydrofuranyl, or represented by the formula ##STR2## wherein R.sup.x is an optionally substituted pyridyl, Y is arylene and .alpha. is a known 5-fluorouracil derivative residue which can be converted to 5-fluorouracil in vivo and which is linked to the carbonyl by an ester or amide linkage.
This is a division, of application Ser. No. 903,824 filed Sept. 3, 1986 now U.S. Pat. No. 4,864,021 which is a continuation-in-part of application Ser. No. 793,056, filed Oct. 30, 1985 and now abandoned.
Priority Data
Oct 30, 1984 [JP] 59-229938 Nov 30, 1984 [JP] 59-259587 Jan 17, 1985 [JP] 60-7190 Mar 25, 1985 [JP] 60-59788 May 09, 1985 [JP] 60-98295 Aug 30, 1985 [JP] 60-192582 Sep 03, 1985 [JP] 60-195223 Jul 25, 1986 [JP] 61-176464 Jul 30, 1986 [JP] 61-181027
The invention relates to cyanopyridone derivatives, to their use in liquid crystal media, liquid crystal devices, anisotropic polymers, optical, electrooptical, decorative, security, cosmetic, diagnostic, pharmaceutic, electric, electronic, charge transport, semiconductor, optical recording, electroluminescent, photoconductor and electrophotographic applications, and to liquid crystal media, polymers and displays comprising them. ##STR00001##
The solid preparation of the invention is prepared by dissolving 3-[3-(6-Benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl]-1-ethoxymethyl-5- fluorouracil (hereinafter referred to as "BOF-A2") and a water-soluble polymer in a organic solvent completely, followed by forming preparation of amorphous powder prepared by removing the organic solvent. The solid preparation is useful to enhance solubility of BOF-A2 and to accomplish rapid absorption of BOF-A2 through the alimentary canal.
